AMH and neuroblastoma: According to the SUCRA ranking plot (Figure 2d), women who were treated with a high dose radiotherapy for a neuroblastoma during infancy were more likely to have impaired AMH levels (SUCRA = 65.4%), followed by the mixed population (SUCRA = 29.6%), meanwhile women who survived a thyroid cancer and were treated with 131-I showed similar percentages to healthy controls (SUCRA = 4.9% and SUCRA = 0.1%, respectively).